AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Anthropic Nears $800 Billion Valuation as Investor Confidence Surges 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
SAN CLEMENTE, Calif., June 01, 2017 -- David Steenblock, an osteopathic physician based in San Clemente, CA, is uniquely qualified to address toxicity in the human body through his use of EDTA Chelation Therapy.
Dr. Steenblock uses EDTA (EthyleneDiamineTetraAcetic Acid) Chelation Therapy, a procedure that removes heavy metals from the blood, and consistently improves blood flow and relieves symptoms associated with atherosclerosis in over 80% of patients treated.
“It’s been observed that patients being treated for acute lead intoxification with EDTA with cardiovascular disease, showed improved stress tolerance and less chest pain with physical exertion, “ said Dr. Steenblock.
Dr. Steenblock believes that the benefits of EDTA chelation can improve circulation; reduce cholesterol levels, decrease high blood pressure; and lower insulin requirements in diabetics.
In addition, Dr. Steenblock uses EDTA Chelation Therapy with a combination of hyperbaric oxygen therapy, leading to significant neurologic improvements for stroke patients.
Dr. David Steenblock is a leading-edge physician in many fields of medicine, from stroke care, to acute brain trauma, to generative and cell-based medicine in the treatment of ALS, Cerebral Palsy and other chronic and degenerative diseases. For more information about Dr. Steenblock’s work in stem cell therapies, visit www.stemcellmd.org.
CONTACT: Irene Doti [email protected]
